Seres Therapeutics Revenue and Competitors

Boston, MA USA

Location

$402.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Seres Therapeutics's estimated annual revenue is currently $155.3M per year.(i)
  • Seres Therapeutics's estimated revenue per employee is $329,660
  • Seres Therapeutics's total funding is $402.8M.
  • Seres Therapeutics's current valuation is $738.5M. (January 2022)

Employee Data

  • Seres Therapeutics has 471 Employees.(i)
  • Seres Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Seres Health is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span metabolic, inflammatory, and infectious diseases.

keywords:N/A

$402.8M

Total Funding

471

Number of Employees

$155.3M

Revenue (est)

0%

Employee Growth %

$738.5M

Valuation

N/A

Accelerator

Seres Therapeutics News

2022-04-19 - Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 14% this week, taking one-year losses to 74%

Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 14% this week, taking one-year losses to 74%. By: Simply...

2022-04-17 - Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of “Hold” from Analysts. Posted by admin on Apr 19th, 2022.

2022-04-06 - Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis - Benzinga

Seres plots for a mid-year approval request for its C. difficile therapeutic, SER-109. Related: Seres Therapeutics' Oral Microbiome Candidate...

2021-11-10 - Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a...

Press Release | Nov 10. 2021 07:07 GMT SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$108.5M48221%N/A
#2
$108.5M48221%N/A
#3
$75M48425%$170M
#4
$88.3M48719%N/A
#5
N/A48932%N/A